Risk of senescence, polypharmacy, and their outcomes in elderly cardiovascular disease patients
Authors:
- 20 March 2025
- book chapter
- Published by Elsevier
- Vol. 104, 351-392
Abstract
No abstract availableKeywords
This publication has 99 references indexed in Scilit:
- Redox signaling in impaired cascades of wound healing: promising approachMolecular Biology Reports, 2023
- Therapeutic Potential of Senolytics in Cardiovascular DiseaseCardiovascular Drugs and Therapy, 2020
- Towards appropriate polypharmacy in older cardiovascular patients: How many medications do I have to take?Clinical Cardiology, 2019
- Drug-drug interactions and their harmful effects in hospitalised patients: a systematic review and meta-analysisEuropean Journal of Clinical Pharmacology, 2017
- Hospital admissions due to adverse drug reactions in the elderly. A meta-analysisEuropean Journal of Clinical Pharmacology, 2017
- Changes in Prescription and Over-the-Counter Medication and Dietary Supplement Use Among Older Adults in the United States, 2005 vs 2011JAMA Internal Medicine, 2016
- Multimorbidity in Older Patients with Cardiovascular DiseaseCurrent Cardiovascular Risk Reports, 2016
- Reducing Inappropriate PolypharmacyJAMA Internal Medicine, 2015
- Hospital admissions/visits associated with drug–drug interactions: a systematic review and meta‐analysisPharmacoepidemiology and Drug Safety, 2014
- Effects of Continuing or Stopping Alendronate After 5 Years of TreatmentJAMA, 2006